These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20525020)

  • 1. Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physicians.
    Ponticelli C; Colombo D; Novara M; Basilisco G;
    Transpl Int; 2010 Nov; 23(11):1126-34. PubMed ID: 20525020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
    Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
    J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Chan L; Mulgaonkar S; Walker R; Arns W; Ambühl P; Schiavelli R
    Transplantation; 2006 May; 81(9):1290-7. PubMed ID: 16699457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
    Sterneck M; Settmacher U; Ganten T; Sarrazin C; Speidel N; Broering D; Heyne N; Paulus E; Mertens M; Fischer L
    Transplant Proc; 2014; 46(1):234-40. PubMed ID: 24507058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
    Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohort.
    Machnicki G; Pefaur J; Gaite L; Linchenco AM; Raimondi C; Schiavelli R; Otero A; Margolis MK
    Health Qual Life Outcomes; 2008 Jul; 6():53. PubMed ID: 18644133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI.
    Kleinman L; Kilburg A; Machnicki G; Faull R; Walker R; Prasad R; Ambuehl P; Bahner U; Margolis MK
    Qual Life Res; 2006 Sep; 15(7):1223-32. PubMed ID: 16972162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.
    Bolin P; Tanriover B; Zibari GB; Lynn ML; Pirsch JD; Chan L; Cooper M; Langone AJ; Tomlanovich SJ
    Transplantation; 2007 Dec; 84(11):1443-51. PubMed ID: 18091520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal-specific patient-reported outcome instruments differentiate between renal transplant patients with or without GI complications.
    Kleinman L; Faull R; Walker R; Ramesh Prasad GV; Ambuehl P; Bahner U
    Transplant Proc; 2005 Mar; 37(2):846-9. PubMed ID: 15848552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
    Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a specific questionnaire for evaluating the impact of gastrointestinal symptoms on the health-related quality of life of transplant patients.
    Ortega F; Bravo J; Cantarell C; Cofán F; Gómez-Bravo MA; Miras M; Crespo-Leiro MG; Ussetti P; Guinea G
    Transplant Proc; 2012 Jun; 44(5):1281-6. PubMed ID: 22664001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.
    Hamdy AF; Bakr MA; Ghoneim MA
    Exp Clin Transplant; 2010 Dec; 8(4):283-91. PubMed ID: 21143093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1α and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
    Vu D; Tellez-Corrales E; Yang J; Qazi Y; Shah T; Naraghi R; Hutchinson IV; Min DI
    Transpl Immunol; 2013 Dec; 29(1-4):155-61. PubMed ID: 23721685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
    Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
    Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.